Burden of Crohn's disease: economics and quality of life aspects in Italy

Viviano Benedini, Nicola Caporaso, Gino Roberto Corazza, Zaccaria Rossi, Giovanni Fornaciari, Mario Cottone, Giorgio Frosini, Mauro Caruggi, Chiara Ottolini, Giorgio L Colombo, Viviano Benedini, Nicola Caporaso, Gino Roberto Corazza, Zaccaria Rossi, Giovanni Fornaciari, Mario Cottone, Giorgio Frosini, Mauro Caruggi, Chiara Ottolini, Giorgio L Colombo

Abstract

Background: This was a prospective observational study designed to evaluate direct and indirect costs and quality of life for patients with Crohn's disease in Italy from the perspectives of the National Health System and of society.

Methods: A total of 162 male and female subjects aged 18-70 years with Crohn's disease in the active phase and a Crohn's Disease Activity Index score ≥150 were included in the study. Subjects were recruited from 25 Italian centers on a consecutive basis. The study consisted of four visits undertaken every 6 months with a follow-up period of 18 months. The study started on September 1, 2006 and was completed on April 12, 2010. Multivariate analyses were carried out on demographic characteristics, treatment costs based on the prescribed daily dose, resource use and other cost parameters, and changes in quality of life using the EQ5D questionnaire.

Results: Cost of illness per subject with Crohn's disease in Italy was estimated to be €15,521 per year, with direct costs representing 76% of total costs. Nonhealth care costs and loss of productivity accounted for 24% of total costs. Societal costs during the first months of enrolment were higher compared with costs in the final months of the study. Quality of life measured by the EQ-5D was 0.558 initially and then increased to 0.739, with a mean value of 0.677 during the enrolment period. The cost of illness was not correlated with age or gender.

Conclusion: The cost of illness was correlated with quality of life; Crohn's disease had a negative impact on subjects' quality of life, and higher costs corresponded to a lower quality of life as measured with the EQ5D. Drug treatment may improve quality of life and reduce hospitalization costs. Our results appear to be in line with the results of other international cost-of-illness studies.

Keywords: Crohn’s disease; EQ5D; EuroQol; cost analysis; cost-of-illness; economic evaluation; quality of life.

Figures

Figure 1
Figure 1
Cost (Euro) per patient by observation period and type of resource used.

References

    1. Achkar JP, Barmada MM, Duerr RH. Perinuclear neutrophil antibodies are not markers for genetic susceptibility or indicators of genetic heterogeneity in familial ulcerative colitis. Am J Gastroenterol. 2002;97:2343–2349.
    1. Lashner BA. Colorectal cancer surveillance for patients with inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002;12:135–143.
    1. Wolf JM, Lashner BA. Inflammatory bowel disease: sorting out the options. Cleve Clinic J Med. 2002;69:621–631.
    1. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53–61.
    1. Peura D, Fennerty B, Lashner B. Osteoporosis for the Gastroenterologist. Hertfordshire, UK: Strategic Consultants International; 2002.
    1. Lucioni C. La qualità della vita nella valutazione economica. Cronache Farmaceutiche, Anno. 1994;XXXVII(6) Italian.
    1. Hodgson T. The state of the art of cost of illness estimates. Adv Health Econ Health Serv Res. 1983;4:129–164.
    1. Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2006.
    1. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32:1134–1139.
    1. Bernstein CN, Papineau N, Zajaczkowki J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677–683.
    1. Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol. 2000;95:524–530.
    1. Silverstein D, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Chron’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49–57.
    1. Feagan BG. Review article: economic issues in Crohn’s disease – assessing the effects of new treatments on health-related quality of life. Aliment Pharmacol Ther. 1999;13( Suppl 4):29–37.
    1. Borgaonkar MR, Irvine JR. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444–454.
    1. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn’s disease. Inflamm Bowel Dis. 2002;8:237–243.
    1. Italian Health Economics Association. Guidelines proposal on how to conduct economic evaluation studies of health programs. Pharmacoeconomics – Italian Research Articles. 2009;11:83–93. Italian.
    1. Health Ministry, DRG Tariff. TUC Tariffa Unica Convenzionale, Conferenza delle Regioni e delle Province Autonome, compensazione interregionale della mobilità sanitaria Testo Unico, Versione in vigore per le attività dell’anno 2010; Rome. May 5, 2011; Italian.
    1. Health Ministry. National Tariff Nomenclator. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale; Ministero della Salute. 2011; 2010. Italian.
    1. Italian Medicines Agency. Negoziazione e rimborsabilità. [Accessed September 23, 2011]. Italian. Available from: .
    1. Banca d’Italia. La ricchezza delle famiglie italiane – anno 2010. [Accessed April 21, 2012]. n. 64-2011 14-12-2011. Italian. Available from: .
    1. ISTAT Istituto Nazionale di Statistica. Nation Institute of Statistics. [Accessed April 21, 2012]. Italian. Available from: .
    1. EQ-5D™ [homepage on the Internet] Rotterdam, The Netherlands: EuroQol Group; [Accessed April 21, 2012]. Available from: .
    1. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208. [No authors listed]
    1. Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQolc-questionnaire. Health Econ. 1993;2:237–246.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72.
    1. Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spiker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996.
    1. Dolan P, Gudex C, Kind P, et al. A Social Tariff for EuroQol: Results from a UK General Population Survey. New York, NY: Centre of Health Economics, University of York; 1995. Discussion Paper 138.
    1. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn’s disease: a payor prospective. Am J Gastroenterol. 2000;95:1955–1960.
    1. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol. 2003;2:121–133.
    1. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265–274.
    1. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess. 2011;15:1–244.
    1. Binion DG, Louis E, Oldenburg B, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis. Can J Gastroenterol. 2011;25:492–496.
    1. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27:609–621.
    1. Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn’s disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497–502.
    1. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357–1363.
    1. Koopmanshap MA. Cost of illness studies: useful for health policy? Pharmacoeconomics. 1998;14:143–148.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere